IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Down 3.3 %

IRIX stock opened at $1.77 on Friday. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $29.45 million, a P/E ratio of -2.64 and a beta of 0.82. The firm has a 50-day moving average price of $1.68 and a 200-day moving average price of $1.83.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same period in the previous year, the business posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.